Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adagene Inc ADR (NQ: ADAG )

2.870 +0.050 (+1.77%)
Streaming Delayed Price Updated: 10:17 AM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 226
Open 2.870
Bid (Size) 2.800 (7)
Ask (Size) 2.880 (2)
Prev. Close 2.820
Today's Range 2.870 - 2.870
52wk Range 2.755 - 20.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
HFCAA News: 128 Chinese Stocks the SEC Could Delist
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding (NYSE:BABA) is the largest... 
Via Benzinga

Performance

YTD
-64.30%
-64.30%
1 Month
-21.37%
-21.37%
3 Month
-57.16%
-57.16%
6 Month
-69.12%
-69.12%
1 Year
-77.92%
-77.92%

More News

Read More
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Via Talk Markets
Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Via Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
Via Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Via Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial
Via Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Via Benzinga
Exposures Product Safety
20 Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Exposures Product Safety
Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adagene Inks Third Cancer Trial Collaboration With Merck
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Via Benzinga
62 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.